SIBN SI-BONE

SI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021

SI-BONE To Report Third Quarter 2021 Financial Results on November 8, 2021

SANTA CLARA, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2021 after market close on Monday, November 8, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (866) 470-1968 for domestic callers or (409) 217-8248 for international callers, using conference ID: 4991983. Live audio of the webcast will be available on the “Investors” section of the company’s website at: . The webcast will be archived and available for replay for at least 90 days after the event.



About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. In 2009, SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, shown to be a source of pain in 15% to 30% of chronic low back pain. Since then, more than 2,500 surgeons have performed a combined total of more than 60,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two RCT’s and over 100 peer reviewed publications, has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System. SI-BONE is leveraging its market leadership position, supported by this proprietary reimbursement advantage, to commercialize other devices intended for surgical treatment of related aspects of the human anatomy. For more information or to join our team, please visit us at -bone.com.

For additional information on the company or the products including risks and benefits, please visit -bone.com.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved.

Investor Contact:

Matt Bacso, CFA





Media Contact:

Joe Powers



EN
18/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SI-BONE

 PRESS RELEASE

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and...

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.7 million, representing growth of 20.6%  U.S. revenue of $46.4 million, representing growth of 21.2%Gross margin of 79.8%, representing an improvement of 75 basis pointsNet loss of $4.6 million, representing an improvement of 30.6%  Positive adjusted EBITDA of $...

 PRESS RELEASE

SI-BONE To Report Third Quarter 2025 Financial Results on November 10,...

SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025 SANTA CLARA, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2025 after market close on Monday, November 10, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: Live audio of the webcast will be avai...

 PRESS RELEASE

SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference...

SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025 SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, September 9, 2025, at 4:00 a.m. Pacific Time/ 07:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by register...

 PRESS RELEASE

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 an...

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.6 million, representing growth of 21.7%U.S. revenue of $46.4 million, representing growth of 22.8%Gross margin of 79.8%, representing an improvement of 80 basis pointsNet loss of $6.2 million, representing an improvement of 31.2%Positive adjusted EBITDA of $1.0 million$145.5 million in cash and equ...

 PRESS RELEASE

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference ...

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, August 12, 2025, at 12:00 p.m. Pacific Time/03:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this lin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch